Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02906631 : Epidemiology and Prognosis of Encephalitis in Intensive Care
PhaseN/A
AgesMin: 18 Years Max: N/A
Eligibility
Inclusion criteria:

- Altered mental status, delirium, or personality changes for a duration > or = 24 h

- At least 2 of the following: 1) fever (>38°C) within 72 hours before or following
hospital admission; 2) new-onset seizures; 3) new-onset focal signs; 4) CSF
pleocytosis > 5 cell / microl; 5) brain parenchyma abnormalities on neuroimaging
compatible with the diagnosis of encephalitis; 6) EEG abnormalities compatible with
the diagnosis of encephalitis.

- Altered mental status with a GCS < or =13 without sedation, or GCS < or =13 before
sedation administration in sedated patients

- CSF analysis performed

- Brain imaging performed (CT/MRI)

- Age >18

Exclusion criteria:

- Time between the first hospitalization for neurologic symptoms in relation with
encephalitis and ICU admission > 7 days

- Purulent bacterial meningitis diagnosed by direct examination or CSF analysis

- Isolated brain abscess.

- Febrile encephalopathy associated with another diagnosis

- Predicted time in ICU < or = 24 hours

- Opposition of close-of-kin, if present at the inclusion, for patient participation in
research.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02906631      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740